<DOC>
	<DOCNO>NCT00429533</DOCNO>
	<brief_summary>The purpose 12-month study determine efficacy dapsone glucocorticoid-sparing agent maintenance phase pemphigus vulgaris .</brief_summary>
	<brief_title>Efficacy Dapsone Steroid Sparing Agent Pemphigus Vulgaris</brief_title>
	<detailed_description>Patients enter trial steroid combination cytotoxic agent need . The steroid dose low dose patient ’ disease control last flare ( see eligibility criterion ) . The patient randomize receive either Dapsone placebo . Treatment start dose 50 mg increase 25 mg increment week hemoglobin show drop 2 gm/dl . The target dose 150 mg patient respond could advance 200 mg daily . After begin treatment , standardize steroid taper commence . A standardized steroid taper suggest taper 10 mg/wk dos 40 mg/day slowly warrant . A slow taper thereafter every day dose schedule would elect accord individual investigator ’ preference . Flares treat increase dose steroid - case mild flare last dose precede flare , case moderate flare 20 mg/day case severe flare 40 mg/day . Tapering resume disease stabilize . Disease activity assess simple scoring system skin , mucosa , sit involve . Laboratory assessment initially weekly become monthly study medication dosage stabilize .</detailed_description>
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Histologic evidence compatible pemphigus vulgaris direct immunofluorescence evidence pemphigus vulgaris . Chronic disease control steroid and/or cytotoxics , e.g . maintenance phase . On prednisone 15 mg/day around 40 mg/day prednisone 15 mg every day ( qod ) around 40 mg qod . Failure taper steroid range 15 mg/day around 40 mg/day 15 mg/qod around 40 qod without flare disease . The steroid dosage recent flare occur less 85 % last ( within 30 day ) dosage control disease , i.e . 85 % baseline steroid dosage . This ensure patient recent acute flare time entry study , rapid steroid taper portion disease flare . Two baseline steroid dosage determine prior flare . It common patient repetitively unable taper certain baseline steroid dose without experience mild flare disease . This baseline dose determine two occasion attempt taper , baseline number average determine dose steroid patient time entry study . No pulse steroid , pulse cyclosphosphamide , plasmapheresis within two month begin protocol . This exclude patient recent acute flare disease may rapid steroid taper portion disease . The patient must maintenance phase , define criterion list e. Patient understand procedure agree participate study program give write informed consent . Patients able taper steroid without recurrence disease . Patients early , severe disease respond high dos prednisone , cytotoxics , plasmapheresis , modality . Contraindications use Dapsone , include severe anemia G6PD deficiency . Patient behavioral problem might interfere compliance . Pregnancy breastfeed . Younger 18 old 80 year age . Since PV rare patient young 18 , decide exclude potentially different population . It unlikely exclude many patient . Dapsone induce hemolytic anemia , would particular problem patient age 80 , likely ischemic heart disease atherosclerotic vascular disease . History allergy dapsone . Ischemic heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>